With the rise in popularity of medications like Ozempic and Wegovy for weight loss, a recent study conducted by researchers from Truveta suggests that tirzepatide leads to more significant weight loss compared to semaglutide.
New Study Findings
Researchers analyzed electronic health records of over 18,000 adults taking tirzepatide or semaglutide between May 2022 and September 2023. The results, published in the JAMA Internal Medicine journal, revealed that individuals on tirzepatide injections were more successful in reaching weight loss targets compared to those on semaglutide.
Key Study Results
- 82% of people on tirzepatide achieved a 5% weight loss compared to about 67% on semaglutide
- Those on tirzepatide were over twice as likely to lose at least 15% of their starting weight
- Average weight loss was consistently higher among tirzepatide users over time
Mechanism of Action
Both tirzepatide and semaglutide mimic the gut hormone GLP-1, which helps regulate insulin production and appetite. However, tirzepatide also stimulates another gut hormone called GIP, potentially enhancing its effects.
FDA Approval
The FDA has approved tirzepatide and semaglutide for treating type 2 diabetes and obesity. Tirzepatide is marketed as Mounjaro and Zepbound by Eli Lilly, while semaglutide is sold as Ozempic and Wegovy by Novo Nordisk.
Concluding Remarks
While the study results align with previous clinical trials, more research is needed to assess the impact of tirzepatide and semaglutide on other health outcomes. The study authors emphasize the importance of further investigation into these medications.
Stay informed with the latest news!
Get updates on local news sent directly to your email inbox.
CNN's Brenda Goodman contributed to this report.
The-CNN-Wire™ & © 2024 Cable News Network, Inc., a Warner Bros. Discovery Company. All rights reserved.